COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME
Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, a polyol, and a combinations of at least two organic acids or salts thereof, wherein the compositions have pH in the range from about 5 to about 7.5, at least one of the organic acids or salts thereof has a pKa in the range from and 6 to about 10. In some embodiments, the second organic acid or a salt thereof has a pKa that is no more than 1.5 units less than the pH.
1 . A composition comprising: (a) alginate; and (b) a combination of at least two organic acids or salts thereof; wherein the composition has a pH in a range from about 5 to about 7.5, at least one of said organic acids or a salt thereof has a pKa in a range from about 6 to about 10.
2 . The composition of claim 1 , wherein a second organic acid or a salt thereof has a pKa in a range from about 4 to about 10.
3 . The composition of claim 2 , further comprising a polyol having 2 to 18 carbon atoms.
4 . The composition of claim 3 , wherein said pH is in a range from about 5.5 to about 6.5.
5 . The composition of claim 3 , wherein at least one of said organic acid or a salt thereof has a pKa that is at least one half unit greater than said pH, and the other organic acid or salt thereof has a pKa that is no more than 1.5 units less than said pH.
6 . The composition of claim 3 , wherein said at least one of said organic acids or a salt thereof is selected from the group consisting of ethylenediaminetetraacetic acid (“EDTA”), hexamethylenediaminetetraacetic acid (“HMDTA”), N-(2-hydroxyethyl)ethylenediamine-N,N′,N′-triacetic acid (“HEEDTA” or HEDTA”), hydroxymethylethylenediaminetriacetic acid (“HMEDTA”), 1,3-diamino-2-propanol-N,N,N′, N′-tetracetic acid, 1,3-diamino-2-propane-N,N,N′,N′-tetracetic acid, ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, ethylenediamine-N,N-diacetic acid (“EDDA”), nicotinic acid, deoxymugineic acid (“DMA”), diethylenetriamine-pentaacetic acid (“DTPA”), 3,6,9-triaza-12-oxa-3,6,9-tricarboxymethylene-10-carboxy-13-phenyl-tridecanoic acid (“B-19036”), and combinations thereof. Other non-limiting examples of aminocarboxylic acids includes cyclic compounds such as 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (“DOTA”), p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (“p-SCN-Bz-DOTA”), 1,4,7,10-tetraazacyclododecane-N,N′,N″-triacetic acid (“DO3A”), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(2-propionic acid) (“DOTMA”), 1,4,7-triazacyclononane-N,N′,N″-triacetic acid (“NOTA”), 1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N′″-tetraacetic acid (“TETA”), triethylene tetraamine hexaacetic acid (“TTHA”), trans-1,2-diaminohexane tetraacetic acid (“CYDTA”), 1,4,7,10-tetraazacyclododecane-1-(2-hydroxypropyl)4,7,10-triacetic acid (“HP-DO3A”), trans-cyclohexanediaminetetraacetic acid (“CDTA”), trans(1,2)-cyclohexane diethylene triamine pentaacetic acid (“CDTPA”), 1-oxa-4,7,10-triazacyclododecane-N,N′,N″-triacetic acid (“OTTA”), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis {3-(4-carboxyl)-butanoic acid}, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetic acid methyl amide), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonic acid), iminodiacetic acid, 2-methoxyethyliminodiacetic acid, 2-methylthioethyliminodiacetic acid, N-2-sulfoethyliminodiacetic acid, N-(carbamoylmethyl)iminodiacetic acid, salts thereof, and combinations thereof.
7 . The composition of claim 6 , wherein said at least one of said organic acids or a salt thereof is selected from the group consisting of EDTA, EDDA, DTPA, nicotinic acid, HEEDTA, DOTA, DO3A, OTTA, salts thereof, and combinations thereof.
8 . The composition of claim 3 , wherein said second organic acid or salt thereof is selected from the group consisting of sorbic acid, acetic acid, dehydroacetic acid, proprionic acid, butyric acid, isobutyric acid, valeric acid, hexanoic acid (caproic acid), heptanoic acid (enanthic acid), octanoic acid (caprylic acid), nonanoic acid (pelargonic acid), decanoic acid (capric acid), (+) camphoric acid, peroxyacetic acid, n-peroxybutyric acid, peroxyformic acid, peroxypropionic acid, malonic acid, dimethylmalonic acid, succinic acid, glutaric acid, β-methylglutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, 1,1-cyclopentanediacetic acid, 1,2-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclohexanedicarboxylic acid, 1,4-cis-cyclohexanedicarboxylic acid, cyclohexanecarboxylic acid, benzoic acid, methoxybenzoic acid, p-n-propoxybenzoic acid, p-n-butoxybenzoic acid, salts thereof, and combinations thereof.
9 . The composition of claim 8 , wherein said second organic acid or salt thereof is selected from the group consisting of sorbic acid, acetic acid, dehydroacetic acid, propionic acid, peroxyacetic acid, peroxypropionic acid, salts thereof, and combinations thereof.
10 . The composition of claim 8 , wherein said second organic acid or salt thereof is selected from the group consisting of succinic acid, glutaric acid, β-methylglutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, 1,1-cyclopentanediacetic acid, 1,2-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclohexanedicarboxylic acid, 1,4-cis-cyclohexanedicarboxylic acid, salts thereof, and combinations thereof.
11 . The composition of claim 6 , wherein said second organic acid or salt thereof is selected from the group consisting of sorbic acid, acetic acid, dehydroacetic acid, proprionic acid, butyric acid, isobutyric acid, valeric acid, hexanoic acid (caproic acid), heptanoic acid (enanthic acid), octanoic acid (caprylic acid), nonanoic acid (pelargonic acid), decanoic acid (capric acid), (+) camphoric acid, peroxyacetic acid, n-peroxybutyric acid, peroxyformic acid, peroxypropionic acid, malonic acid, dimethylmalonic acid, succinic acid, glutaric acid, 0-methylglutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, 1,1-cyclopentanediacetic acid, 1,2-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclohexanedicarboxylic acid, 1,4-cis-cyclohexanedicarboxylic acid, cyclohexanecarboxylic acid, benzoic acid, methoxybenzoic acid, p-n-propoxybenzoic acid, p-n-butoxybenzoic acid, salts thereof, and combinations thereof.
12 . The composition of claim 11 , wherein said second organic acid or salt thereof is selected from the group consisting of sorbic acid, acetic acid, dehydroacetic acid, propionic acid, peroxyacetic acid, peroxypropionic acid, salts thereof, and combinations thereof.
13 . The composition of claim 11 , wherein said second organic acid or salt thereof is selected from the group consisting of succinic acid, glutaric acid, β-methylglutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, 1,1-cyclopentanediacetic acid, 1,2-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclohexanedicarboxylic acid, 1,4-cis-cyclohexanedicarboxylic acid, salts thereof, and combinations thereof.
14 . The composition of claim 11 , wherein said polyol glycerin, ethylene glycol, propylene glycol, sorbitol, mannitol, xylitol, monosaccharides, disaccharides, and combinations thereof.
15 . The composition of claim 14 , wherein said pH is in a range from about 5.5 to about 6.8.
16 . The composition of claim 3 , wherein said second organic acid has a pKa that is no more than 1.5 units less than the pH of the composition.
17 . The composition of claim 16 , wherein said second organic acid has a pKa that is no more than 1 unit less than the pH of the composition.
18 . A composition for reducing, ameliorating, treating, or preventing a condition of dry eye, the composition consisting essentially of: (a) alginate in a concentration from about 0.01 to about 2 percent by weight of the total composition; (b) at least two organic acids or salts thereof, each present in a concentration from about 0.05 to about 0.5 percent by weight of the total composition; (c) glycerin in a concentration from about 0.1 to about 1 percent by weight of the total composition; and (d) water; wherein the composition has a pH from about 5.5 to about 6.5, and at least one of said organic acids or a salt thereof has a pKa value that is at least one half unit greater than said pH.
19 . The composition of claim 18 , wherein said alginate is present in a concentration in the range from about 0.1 to 1 percent by weight of the total composition.
20 . A composition for reducing, ameliorating, treating, or preventing a condition of dry eye, the composition consists essentially of: (a) alginate in a concentration from about 0.1 to about 0.5 percent by weight of the total composition; (b) at least two organic acids or salts thereof, each present in a concentration from about 0.05 to about 0.5 percent by weight of the total composition; (c) glycerin in a concentration from about 0.1 to about 1 percent by weight of the total composition; (d) propylene glycol in a concentration from about 0.1 to about 1 percent by weight of the total composition; (e) a buffering system or agent; and (f) water; wherein the composition has a pH from about 5.5 to about 6.5; at least one of said organic acids or a salt thereof has a pKa value that is at least one half unit greater than said pH; and a second organic acid or a salt thereof has a pKa that is no more than 1.5 units less than said pH.
21 . A composition for reducing, ameliorating, treating, or preventing a condition of dry eye, the composition consists essentially of: (a) alginate in a concentration from about 0.1 to about 0.5 percent by weight of the total composition; (b) at least two organic acids or salts thereof, each present in a concentration from about 0.05 to about 0.5 percent by weight of the total composition; (c) glycerin in a concentration from about 0.1 to about 1 percent by weight of the total composition; (d) propylene glycol in a concentration from about 0.1 to about 1 percent by weight of the total composition; (e) a buffering system or agent; and (f) water; wherein the composition has a pH from about 5.5 to about 6.5, at least one of said organic acid or salt thereof has a pKa value that is at least one half unit greater than said pH and a second organic acid or salt thereof has a pKa value that is greater than about 4.5.
22 . The composition of claim 21 , wherein the composition is a solution, an emulsion, a dispersion, a gelable composition, or a gel.
23 . A composition for reducing, ameliorating, treating, or preventing a condition of dry eye, the composition consists essentially of: (a) alginate in a concentration from about 0.1 to about 0.5 percent by weight of the total composition; (b) two organic acids or salts thereof, each present in a concentration from about 0.05 to about 0.5 percent by weight of the total composition; (c) glycerin in a concentration from about 0.1 to about 1 percent by weight of the total composition; (d) propylene glycol in a concentration from about 0.1 to about 1 percent by weight of the total composition; (e) a buffering system or agent; and (f) water; wherein the composition has a pH from about 5.5 to about 6.5, one of said organic acid or salt thereof is EDTA or a salt thereof; and a second organic acid or salt thereof is sorbic acid or a salt thereof.
24 . A method of reducing, ameliorating, treating, or preventing a condition of dry eye, the method comprising administering to an eye affected by said condition a composition that comprises: (a) alginate; and (b) a combination of at least two organic acids or salts thereof; wherein the composition has a pH in a range from about 5 to about 7.5, at least one of said organic acids or a salt thereof has a pKa in a range from about 6 to about 10.
25 . The method of claim 24 , wherein said at least one of said organic acids or a salt thereof is selected from the group consisting of ethylenediaminetetraacetic acid (“EDTA”), hexamethylenediaminetetraacetic acid (“HMDTA”), N-(2-hydroxyethyl)ethylenediamine-N,N′,N′-triacetic acid (“HEEDTA” or HEDTA”), hydroxymethylethylenediaminetriacetic acid (“HMEDTA”), 1,3-diamino-2-propanol-N,N,N′, N′-tetracetic acid, 1,3-diamino-2-propane-N,N,N′,N′-tetracetic acid, ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, ethylenediamine-N,N-diacetic acid (“EDDA”), nicotinic acid, deoxymugineic acid (“DMA”), diethylenetriamine-pentaacetic acid (“DTPA”), 3,6,9-triaza-12-oxa-3,6,9-tricarboxymethylene-10-carboxy-13-phenyl-tridecanoic acid (“B-19036”), and combinations thereof. Other non-limiting examples of aminocarboxylic acids includes cyclic compounds such as 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (“DOTA”), p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (“p-SCN-Bz-DOTA”), 1,4,7,10-tetraazacyclododecane-N,N′,N″-triacetic acid (“DO3A”), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(2-propionic acid) (“DOTMA”), 1,4,7-triazacyclononane-N,N′,N″-triacetic acid (“NOTA”), 1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N′″-tetraacetic acid (“TETA”), triethylene tetraamine hexaacetic acid (“TTHA”), trans-1,2-diaminohexane tetraacetic acid (“CYDTA”), 1,4,7,10-tetraazacyclododecane-1-(2-hydroxypropyl)-4,7,10-triacetic acid (“HP-DO3A”), trans-cyclohexanediaminetetraacetic acid (“CDTA”), trans(1,2)-cyclohexane diethylene triamine pentaacetic acid (“CDTPA”), 1-oxa-4,7,10-triazacyclododecane-N,N′,N″-triacetic acid (“OTTA”), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis {3-(4-carboxyl)-butanoic acid}, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetic acid methyl amide), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonic acid), iminodiacetic acid, 2-methoxyethyliminodiacetic acid, 2-methylthioethyliminodiacetic acid, N-2-sulfoethyliminodiacetic acid, N-(carbamoylmethyl)iminodiacetic acid, salts thereof, and combinations thereof.
26 . The method of claim 24 , wherein said second organic acid or salt thereof is selected from the group consisting of sorbic acid, acetic acid, dehydroacetic acid, proprionic acid, butyric acid, isobutyric acid, valeric acid, hexanoic acid (caproic acid), heptanoic acid (enanthic acid), octanoic acid (caprylic acid), nonanoic acid (pelargonic acid), decanoic acid (capric acid), (+) camphoric acid, peroxyacetic acid, n-peroxybutyric acid, peroxyformic acid, peroxypropionic acid, malonic acid, dimethylmalonic acid, succinic acid, glutaric acid, β-methylglutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, 1,1-cyclopentanediacetic acid, 1,2-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclohexanedicarboxylic acid, 1,4-cis-cyclohexanedicarboxylic acid, cyclohexanecarboxylic acid, benzoic acid, methoxybenzoic acid, p-n-propoxybenzoic acid, p-n-butoxybenzoic acid, salts thereof, and combinations thereof.
27 . The method of claim 25 , wherein said second organic acid or salt thereof is selected from the group consisting of sorbic acid, acetic acid, dehydroacetic acid, proprionic acid, butyric acid, isobutyric acid, valeric acid, hexanoic acid (caproic acid), heptanoic acid (enanthic acid), octanoic acid (caprylic acid), nonanoic acid (pelargonic acid), decanoic acid (capric acid), (+) camphoric acid, peroxyacetic acid, n-peroxybutyric acid, peroxyformic acid, peroxypropionic acid, malonic acid, dimethylmalonic acid, succinic acid, glutaric acid, β-methylglutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, 1,1-cyclopentanediacetic acid, 1,2-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclopentanedicarboxylic acid, 1,3-trans-cyclohexanedicarboxylic acid, 1,4-cis-cyclohexanedicarboxylic acid, cyclohexanecarboxylic acid, benzoic acid, methoxybenzoic acid, p-n-propoxybenzoic acid, p-n-butoxybenzoic acid, salts thereof, and combinations thereof.
28 . A method of reducing, ameliorating, treating, or preventing a condition of dry eye, the method comprising administering to an eye affected by said condition a composition that consists essentially of: (a) alginate in a concentration from about 0.1 to about 0.5 percent by weight of the total composition; (b) at least two organic acids or salts thereof, each present in a concentration from about 0.05 to about 0.5 percent by weight of the total composition; (c) glycerin in a concentration from about 0.1 to about 1 percent by weight of the total composition; (d) propylene glycol in a concentration from about 0.1 to about 1 percent by weight of the total composition; (e) a buffering system or agent; and (f) water; wherein the composition has a pH from about 5.5 to about 6.5; at least one of said organic acids or a salt thereof has a pKa value that is at least one half unit greater than said pH; and a second organic acid or a salt thereof has a pKa that is no more than 1.5 units less than said pH.
29 . A method of reducing, ameliorating, treating, or preventing a condition of dry eye, the method comprising administering to an eye affected by said condition a composition consists essentially of: (a) alginate in a concentration from about 0.1 to about 0.5 percent by weight of the total composition; (b) at least two organic acids or salts thereof, each present in a concentration from about 0.05 to about 0.5 percent by weight of the total composition; (c) glycerin in a concentration from about 0.1 to about 1 percent by weight of the total composition; (d) propylene glycol in a concentration from about 0.1 to about 1 percent by weight of the total composition; (e) a buffering system or agent; and (f) water; wherein the composition has a pH from about 5.5 to about 6.5, at least one of said organic acid or salt thereof has a pKa value that is at least one half unit greater than said pH and a second organic acid or salt thereof has a pKa value that is greater than about 4.5.
30 . A method of reducing, ameliorating, treating, or preventing a condition of dry eye, the method comprising administering to an eye affected by said condition a composition consists essentially of: (a) alginate in a concentration from about 0.1 to about 0.5 percent by weight of the total composition; (b) two organic acids or salts thereof, each present in a concentration from about 0.05 to about 0.5 percent by weight of the total composition; (c) glycerin in a concentration from about 0.1 to about 1 percent by weight of the total composition; (d) propylene glycol in a concentration from about 0.1 to about 1 percent by weight of the total composition; (e) a buffering system or agent; and (f) water; wherein the composition has a pH from about 5.5 to about 6.5, one of said organic acid or salt thereof is EDTA or a salt thereof; and a second organic acid or salt thereof is sorbic acid or a salt thereof.
31 . A method for preparing a composition, the method comprising combining (a) alginate; (b) a combination of at least two organic acids or salts thereof; (c) a polyol; and a pharmaceutically acceptable carrier, to form a mixture; wherein the composition has a pH in a range from about 5 to about 7.5; at least one of said organic acids or a salt thereof has a pKa in a range from about 6 to about 10; and a second organic acid or a salt thereof has a pKa in a range from about 4 to about 10.
32 . The method of claim 31 , wherein said combining further comprises adding a buffering system or agent to the mixture.